MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
6.04
+0.03 (0.50%)
At close: Jan 21, 2025, 4:00 PM
6.05
+0.01 (0.16%)
After-hours: Jan 21, 2025, 6:51 PM EST
MannKind Revenue
MannKind had revenue of $70.08M in the quarter ending September 30, 2024, with 36.73% growth. This brings the company's revenue in the last twelve months to $267.20M, up 51.35% year-over-year. In the year 2023, MannKind had annual revenue of $198.96M with 99.42% growth.
Revenue (ttm)
$267.20M
Revenue Growth
+51.35%
P/S Ratio
6.15
Revenue / Employee
$645,411
Employees
414
Market Cap
1.67B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
MNKD News
- 15 days ago - MannKind Expands Executive Leadership Team - GlobeNewsWire
- 5 weeks ago - MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets - Seeking Alpha
- 5 weeks ago - MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®) - GlobeNewsWire
- 5 weeks ago - CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India - GlobeNewsWire
- 2 months ago - MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - MannKind to Present at 2024 UBS Healthcare Conference - GlobeNewsWire
- 2 months ago - MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases - GlobeNewsWire